Metabolism of bergamottin by cytochromes P4502B6 and 3A5

被引:30
作者
Kent, Ute M.
Lin, Hsia-lien
Noon, Kathleen R.
Harris, Danni L.
Hollenberg, Paul F.
机构
[1] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA
[2] Mol Res Inst, Mountain View, CA USA
关键词
D O I
10.1124/jpet.105.099887
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochromes P450 (P450) 2B6 and 3A5 are inactivated by bergamottin (BG). P450 2B6 metabolized BG primarily to M3 and M4 and one minor metabolite (M1). The metabolites were analyzed, and the data indicated that M1 was bergaptol, M3 was 5'-OH-BG, and M4 was a mixture of 6'- and 7' -OH-BG. Because 6'- and 7'- OH-BG were the primary metabolites, it suggested that P450 2B6 preferentially oxidized the geranyloxy chain of BG. Metabolism of BG by P450 3A5 resulted in three major metabolites: [ bergaptol, M3 (5'-OH-BG), and M5 (2'- OH- BG)], and two minor metabolites [M2 (6', 7'- dihydroxyBG) and M4 (6'- and 7'-OH-BG)]. Because bergaptol was the most abundant metabolite formed, it suggested that P450 3A5 metabolized BG mainly by cleaving the geranyl-oxy chain. Molecular modeling studies confirmed that docking of BG in the P450 2B6 active site favors oxidation in the terminal region of the geranyl-oxy chain, whereas positioning the 2'-carbon of BG nearest the heme iron is preferred by P450 3A5. Glutathione (GSH)-BG conjugates were formed by both P450. Each enzyme predominantly formed conjugates with m/z values of 662. Tandem mass spectrometry analysis of the GSH conjugates indicated that the oxidation forming a reactive intermediate occurred on the furan moiety of BG, presumably through the initial formation of an epoxide at the furan double bond. The data indicate that oxidation of the geranyl-oxy chain resulted in the formation of stable metabolites of BG, whereas oxidation of the furan ring produced reactive intermediates that may be responsible for binding to and inactivating P450 2B6 and 3A4.
引用
收藏
页码:992 / 1005
页数:14
相关论文
共 43 条
[1]   Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients [J].
Bailey, DG ;
Dresser, GR ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :468-477
[2]   P450 active site architecture and reversibility:: Inactivation of cytochromes p450 2B4 and 2B4 T302A by tert-butyl acetylenes [J].
Blobaum, AL ;
Harris, DL ;
Hollenberg, PF .
BIOCHEMISTRY, 2005, 44 (10) :3831-3844
[3]   The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P4502B6 exhibits alterations in substrate metabolism and inactivation [J].
Bumpus, NN ;
Sridar, C ;
Kent, UM ;
Hollenberg, PF .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) :795-802
[4]   INHIBITION AND INACTIVATION OF MURINE HEPATIC ETHOXYRESORUFIN AND PENTOXYRESORUFIN O-DEALKYLASE BY NATURALLY-OCCURRING COUMARINS [J].
CAI, YN ;
BENNETT, D ;
NAIR, RV ;
CESKA, O ;
ASHWOODSMITH, MJ ;
DIGIOVANNI, J .
CHEMICAL RESEARCH IN TOXICOLOGY, 1993, 6 (06) :872-879
[5]   A graph-theory algorithm for rapid protein side-chain prediction [J].
Canutescu, AA ;
Shelenkov, AA ;
Dunbrack, RL .
PROTEIN SCIENCE, 2003, 12 (09) :2001-2014
[6]   Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts [J].
Ding, XX ;
Kaminsky, LS .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2003, 43 :149-173
[7]   cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome p450 [J].
Domanski, TL ;
Finta, C ;
Halpert, JR ;
Zaphiropoulos, PG .
MOLECULAR PHARMACOLOGY, 2001, 59 (02) :386-392
[8]   Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development [J].
Evans, DC ;
Watt, AP ;
Nicoll-Griffith, DA ;
Baillie, TA .
CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (01) :3-16
[9]  
Faucette SR, 2000, DRUG METAB DISPOS, V28, P1222
[10]   Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy [J].
Friesner, RA ;
Banks, JL ;
Murphy, RB ;
Halgren, TA ;
Klicic, JJ ;
Mainz, DT ;
Repasky, MP ;
Knoll, EH ;
Shelley, M ;
Perry, JK ;
Shaw, DE ;
Francis, P ;
Shenkin, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) :1739-1749